DexCom, Inc. Earnings Recaps
Dexcom’s shares rose 3.0% after earnings. Revenue grew 11% year over year, with 14% growth in the U.S., while the company highlighted continued U.S. share gains and progress toward broader CGM access.
Key takeaways
- Third-quarter revenue increased 11% year over year on both a reported and organic basis.
- U.S. revenue grew 14%; Dexcom said it gained share, with the largest increase among customers with type 2 diabetes, including those not on insulin.
- Dexcom expects a CMS decision on type 2 non-insulin coverage this year. Its CONNECT trial found a 0.9% A1c difference between the CGM and control groups over six months.
- G7 15 Day adoption built during the quarter; Dexcom remains on track to convert nearly 50% of its U.S. customer base by year-end.
- Dexcom reported a 4- to 5-point improvement in 15 Day survivability as the updated adhesive rolls out.
DexCom's shares gained 11.1% following Q2 earnings as strong product demand, consistent new customer growth, and positive clinical trial results for non-insulin type 2 diabetes patients clearly outpaced concerns. Investors appear encouraged by solid revenue growth and broadening commercial coverage despite limited detail on potential margin pressures or segment weaknesses. Key Takeaways:
Key takeaways
- Reported 13% year-over-year revenue growth, with 12% organic growth, driven by broad global demand for DexCom CGM systems.
- New customer starts remained at record levels, including a sequential increase in the US market.
- Positive clinical trial results (Connect study) demonstrated a 1.6% A1C improvement in type 2 diabetes patients not on insulin, supporting reimbursement expansion.
- Coverage now includes more than 7 million non-insulin type 2 diabetes patients across major US commercial PBMs.
- Announced a $1 billion share repurchase plan for 2026, signaling confidence in capital allocation and underlying business stability.
DexCom shares closed up 6.6% following first quarter earnings, as results and management commentary highlighted outperformance in both revenue growth and key commercial execution, particularly across the underpenetrated type 2 diabetes population.
Key takeaways
- Revenue grew 15% year-over-year (organic revenue +12%), driven by expanded global demand, new product launches, and active user base growth.
- U.S. growth was led by significant share gains among type 2 diabetes patients not using insulin, underpinned by increasing reimbursement and broadening clinical adoption.
- Recent commercial wins, including a new reimbursement agreement with Prime Therapeutics, are on track to expand U.S. commercial coverage for non-insulin type 2 patients to over 7 million lives by year-end.
- Management cited strong feedback and adoption trends for the new G7 15-day sensor system, which launched across all channels in the quarter and is receiving high marks for both wear time and enhanced accuracy.
- Forward pipeline includes expected near-term distribution of new patch technology (FDA cleared), expanded software offerings, and a forthcoming major randomized controlled trial readout at the ADA’s 2026 Scientific Sessions, further supporting the case for expanded payer coverage.
DexCom reported strong third-quarter 2025 results with 20% organic revenue growth, driven by expanding customer access and innovative product offerings in the continuous glucose monitoring (CGM) space.
Key takeaways
- Achieved 20% organic revenue growth year-over-year, reflecting robust market demand and competitive positioning.
- Expanded CGM access to nearly 6 million U.S. type 2 diabetes patients, targeting full coverage for over 25 million individuals.
- Introduced DexCom Smart Basal, an innovative titration module designed to enhance basal insulin management and improve patient adherence.
- Stelo product surpassed $100 million in revenue within its first year, indicating strong market traction and consumer interest in CGM for metabolic health.
- Continued advancement of G7 15-day system rollout, bolstered by successful reimbursement strategies.
DexCom achieved a robust 15% organic revenue growth in Q2 2025, driven by strong demand in the U.S. and significant progress in expanding insurance coverage for type 2 diabetes patients.
Key takeaways
- Launched type 2 non-insulin reimbursement, establishing coverage for nearly 6 million patients through the three largest PBMs in the U.S.
- Strong market share growth driven by heightened sales force effectiveness and increased access to healthcare providers.
- Over 400,000 downloads of the Stelo app reflect growing consumer interest in glucose monitoring and health wearables.
- Anticipating a successful second-half launch of the 15-day G7 System, with FDA clearance and reimbursement discussions on track.
- Introduced innovative AI features across products to enhance user experience and simplify diabetes management.